Mark McKenna

Mark C. McKenna has more than two decades of experience building and leading life sciences companies across the pharmaceutical, medical device, consumer health and diagnostics sectors. He is the founder of Mirador Therapeutics, Inc., a San Diego based biotechnology company and has served as its Chairman since January2024. Mr. McKenna has been a director of New Amsterdam Pharma Company N.V.(Nasdaq: NAMS) since July 2024 and of Helix Acquisition Corp. III (Nasdaq: HLXC) since January 2026. He has also been a Venture Partner at ARCH Venture Partners since February 2024 and a Senior Advisor to Fairmount Funds Management LLC since October 2023.

From August 2023 until its acquisition by AbbVie Inc. (NYSE: ABBV) in September 2026 for approximately $10.9 billion, Mr. McKenna served as Chairman of the board of directors of Apogee Therapeutics, Inc. (formerly Nasdaq: APGE). From 2019 until its acquisition by Merck & Co., Inc. for approximately $10.8 billion in June 2023, he served as Chairman, President and Chief Executive Officer of Prometheus Biosciences, Inc. (formerly Nasdaq: RXDX), a clinical-stage biotechnology company that pioneered a precision medicine approach to immune-mediated diseases.

Before joining Prometheus, Mr. McKenna was a corporate officer of Bausch Health Companies Inc. and President of its subsidiary, Salix Pharmaceuticals. Before that, he spent more than a decade at Bausch + Lomb, most recently as Senior Vice President and General Manager of U.S. Vision Care. He began his career at Johnson & Johnson, where he held positions of increasing responsibility.

Mr. McKenna was named an EY Entrepreneur Of The Year in 2023. He founded the McKenna Life Sciences, Business and Entrepreneurship Program at Arizona State University. He holds a B.S. in Marketing from the W. P. Carey School of Business at Arizona State University and an M.B.A. from Azusa Pacific University, and he completed the Wharton Fellows Program at the Wharton School of the University of Pennsylvania.